An Extension Trial of Inclisiran in Participants With Cardiovascular Disease and High Cholesterol
A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 382 participants.
Also called NCT03060577
- Study
- In this atlas
Overview
- Design
- Interventional study; non-randomized; no masking; primary purpose treatment
- Phase
- Phase 2
- Enrolled
- 382 participants
- Sponsor
- Registry
-
NCT03060577 -
2016-003815-37
-
- Other papers using this trial's data
- Long-term efficacy and safety of inclisiran in patients with high cardiovascular risk and elevated LDL cholesterol (ORION-3): results from the 4-year open-label extension of the ORION-1 trial
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States, Canada, Germany, Netherlands, United Kingdom
- Registry status
- Completed
Technical summary
Registry record NCT03060577. Non-randomized; no masking; primary purpose treatment. Start 2017-04-27 (actual); primary completion 2021-12-17 (actual). Results posted on 2023-03-24.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- An Extension Trial of Inclisiran in Participants With Cardiovascular Disease and High Cholesterol
- Acronym
- ORION-3
- Condition
- Atherosclerotic Cardiovascular Disease
- Condition
- Symptomatic Atherosclerosis
- Condition
- Type2 Diabetes
- Condition
- Familial Hypercholesterolemia
- Intervention (Drug)
- Inclisiran
- Intervention (Drug)
- Evolocumab
- Lead sponsor
- Novartis Pharmaceuticals
Record details
- Record id
cardio:ct-nct03060577- Content hash
717da5bf7cb9e076f6ce38a886c70bb4e571163143f3d7fb5d98329195c5900c